Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference
Achieve Life Sciences (NASDAQ: ACHV), a clinical-stage pharmaceutical firm, will participate in the Spring Into Action Best Ideas Virtual Investor Conference from May 16-20, 2022. Achieve focuses on the development of cytisinicline, a plant-based product aimed at smoking cessation and nicotine addiction. This investigational candidate has not yet received FDA approval. With tobacco-related deaths exceeding eight million globally, cytisinicline aims to mitigate this crisis by targeting nicotine receptors in the brain. For access to the conference, registration is required.
- Participation in the Spring Into Action Best Ideas Virtual Investor Conference may enhance investor interest.
- Cytisinicline addresses a significant global health issue, potentially appealing to a large market.
- Evidence suggests cytisinicline could effectively aid smoking cessation by influencing nicotine withdrawal.
- Cytisinicline remains an investigational product and has not obtained FDA approval.
- There are inherent risks regarding clinical development and market acceptance of cytisinicline.
- Funding for further development of cytisinicline is uncertain, posing financial risks.
SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the Spring Into Action Best Ideas Virtual Investor Conference. The conference is taking place virtually from May 16 - 20, 2022. Details for access to the presentation are as follows:
Spring Into Action Virtual Conference
Date: Monday, May 16, 2022
Time: 1:00 PM EDT
Event: Presentation
To register for the conference, click HERE.
For additional information on Achieve visit https://ir.achievelifesciences.com
About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.1,2 More than
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. For more information on cytisinicline and Achieve visit www.achievelifesciences.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, safety and tolerability of cytisinicline, the ability to discover and develop new uses for cytisinicline, including but not limited to as an e-cigarette cessation product, the development and effectiveness of new treatments, and the intention to submit cytisinicline to the FDA for approval. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve’s intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of the Russian military action in Ukraine; risks related to the impact on our business of the COVID-19 pandemic or similar public health crises and the other factors described in the risk factors set forth in Achieve’s filings with the Securities and Exchange Commission from time to time, including Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.
Investor Relations Contact
Rich Cockrell
achv@cg.capital
(404) 736-3838
Media Contact
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485
References
1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
2 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.
FAQ
What is Achieve Life Sciences' stock symbol?
When will Achieve Life Sciences present at the Spring Into Action Conference?
What is cytisinicline?
Is cytisinicline approved by the FDA?
What health issue is Achieve Life Sciences addressing with cytisinicline?
